Major Depressive Disorder (MDD) adjunct
CYBNCybinCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for CYB003 (Deuterated Psilocin Oral) in Major Depressive Disorder (MDD) adjunct. The expected timing is based on the latest available company guidance and may change.
06/29/26:- APPROACH surpassed 88% enrollment. Q4 2026 topline reiterated. EMBRACE enrollment underway. NDA possible in 2028. 07/21/26:- APPROACH enrollment completed (223). EMBRACE enrollment continues; EXTEND rollover ongoing. Q4 2026 topline reiterated. 08/14/26:- APPROACH enrollment completed and topline data will be reported in Q4 2026. EMBRACE enrollment and EXTEND rollover continue.
Verification
Confirm timing and program details against the company announcement or filing.